| Q38921522 | A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer |
| Q47585189 | Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas |
| Q74342330 | Alternative methods of extracting telomerase activity from human tumor samples |
| Q41553161 | Artificial neural network in diagnosis of urothelial cell carcinoma in urine cytology |
| Q35769740 | Best practice in primary care pathology: review 2 |
| Q26775990 | Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise |
| Q80296315 | Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma |
| Q36770389 | Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests |
| Q73617276 | Bladder tumor antigen assay as compared to voided urine cytology in the diagnosis of bladder cancer |
| Q36363221 | Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers |
| Q35190183 | Bladder tumour antigen (BTA stat) test compared to the urine cytology in the diagnosis of bladder cancer: A meta-analysis |
| Q51729617 | CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma. |
| Q40762408 | Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors |
| Q73427678 | Comparison of human telomerase reverse transcriptase messenger RNA and telomerase activity as urine markers for diagnosis of bladder carcinoma |
| Q73746302 | Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology |
| Q75193535 | Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder |
| Q79365023 | Construction of a global score quantifying allelic imbalance among biallelic SIDP markers in bladder cancer |
| Q24654929 | Critical evaluation of urinary markers for bladder cancer detection and monitoring |
| Q57452994 | Current Use and Promise of Urinary Markers for Urothelial Cancer |
| Q35192390 | Current bladder cancer tests: unnecessary or beneficial? |
| Q34729816 | Current concepts of tumor markers in bladder cancer |
| Q73739765 | Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker |
| Q73599197 | Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor |
| Q80136957 | Detection of survivin mRNA in urine of patients with superficial urothelial cell carcinomas |
| Q37507532 | Diagnosis of urothelial carcinoma from urine |
| Q34785719 | Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis |
| Q36791094 | Epigenetic markers for bladder cancer in urine |
| Q44062356 | Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma |
| Q46304737 | Exclusion of the uniform tetraploid cells significantly improves specificity of the urine FISH assay |
| Q73592455 | Expression of the RNA component of human telemorase (hTR) in ThinPrep preparations from bladder washings |
| Q34135237 | External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort |
| Q76368230 | Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder |
| Q34950660 | Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma |
| Q80608577 | ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma |
| Q35013231 | Immunohistochemical detection of hTERT in urothelial lesions: a potential adjunct to urine cytology |
| Q33534847 | In-depth investigation of the molecular pathogenesis of bladder cancer in a unique 26-year old patient with extensive multifocal disease: a case report |
| Q73784078 | Limitations of urinary telomerase activity measurement in urothelial cancer |
| Q50256258 | Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer |
| Q58292005 | Metastatic Cervical Lymph Nodes from Urogenital Tract Carcinoma: A Diagnostic and Therapeutic Challenge |
| Q36526271 | Molecular markers in bladder cancer: a critical appraisal |
| Q37671590 | Molecular screening for bladder cancer: progress and potential. |
| Q35782279 | Non-invasive methods of bladder cancer detection |
| Q54485236 | Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine. |
| Q40007727 | Nuclear matrix protein 22 as adjunct to urine cytology and cystoscopy in follow-up of superficial TCC of urinary bladder |
| Q38985274 | Nucleophosmin1 associated with drug resistance and recurrence of bladder cancer |
| Q36090960 | Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder |
| Q73784111 | Preliminary report of the clinical performance of a new urinary bladder cancer antigen test: comparison to voided urine cytology in the detection of transitional cell carcinoma of the bladder |
| Q35720587 | Primary care update on kidney and bladder cancer: a urologic perspective |
| Q57825491 | Qualitative and Quantitative Detection of Urinary Human Complement Factor H-Related Protein (BTA stat and BTA TRAK) and Fragments of Cytokeratins 8, 18 (UBC Rapid and UBC IRMA) as Markers for Transitional Cell Carcinoma of the Bladder |
| Q81133196 | Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma |
| Q47411078 | Recent Developments in the Search for Urinary Biomarkers in Bladder Cancer |
| Q83612735 | Reflex UroVysion testing in suspicious urine cytology cases |
| Q34174003 | Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses |
| Q74826156 | Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis |
| Q42353172 | Telomerase activity detected by quantitative assay in bladder carcinoma and exfoliated cells in urine. |
| Q46737170 | Telomerase activity in bilharzial bladder cancer. Prognostic implications |
| Q34464335 | Telomerase and cancer: time to move from a promising target to a clinical reality. |
| Q42183561 | Telomerase detection in the diagnosis and prognosis of cancer |
| Q33851139 | Telomerase in human bladder cancer |
| Q33665866 | Telomerase: Dr Jekyll or Mr Hyde? |
| Q77291804 | Telomerase: diagnostics, cancer therapeutics and tissue engineering |
| Q34535701 | Telomerase: its clinical relevance in the diagnosis of bladder cancer |
| Q34593359 | Telomere and telomerase in oncology |
| Q74613405 | The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma |
| Q76352148 | The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer |
| Q33851127 | The application of human complement factor H-related protein (BTA TRAK) in monitoring patients with bladder cancer |
| Q42721217 | The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine |
| Q36418397 | The management of superficial transitional cell carcinoma of the bladder. |
| Q85962074 | The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study |
| Q57989694 | The use of Urovysion™ fluorescence in situ hybridization in the diagnosis and surveillance of non-urothelial carcinoma of the bladder |
| Q73676341 | The use of molecular diagnostics in bladder cancer |
| Q38285466 | The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review |
| Q33851118 | The utility of fibrin/fibrinogen degradation products in superficial bladder cancer |
| Q33814654 | Time to abandon testing for microscopic haematuria in adults? |
| Q36669984 | Urinary bladder tumor markers |
| Q33936517 | Urinary markers of malignancy. |
| Q34073973 | Urine cytology and adjunct markers for detection and surveillance of bladder cancer |
| Q33851115 | Urine cytology. It is still the gold standard for screening? |
| Q38140308 | Urine markers for detection and surveillance of bladder cancer |
| Q34770052 | Urine telomerase: an important marker in the diagnosis of bladder cancer |
| Q77057893 | Urine tissue-polypeptide-specific antigen (TPS) as a marker for bladder cancer |
| Q38967481 | Urothelial Bladder Cancer Urinary Biomarkers |
| Q54665313 | Use of polymerase chain reaction analysis of urinary DNA to detect bladder carcinoma. |
| Q73764106 | Usefulness of the BTA STAT Test for the diagnosis of bladder cancer |
| Q42514714 | Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma |
| Q35796503 | Value of urinary cytology in the diagnosis and management of urinary tract malignancies |
| Q73333021 | [NMP-22 in the diagnosis of bladder cancer] |
| Q53377323 | [Non-invasive urinary diagnosis of bladder cancer. What do we know?]. |
| Q83353070 | [Tumor marker tests in bladder cancer] |
| Q73724891 | [Tumor markers of bladder cancer] |
| Q79990260 | [Value of urinary markers in the diagnosis and follow-up of urothelial bladder tumours] |